Welcome to our dedicated page for Phibro Animal news (Ticker: PAHC), a resource for investors and traders seeking the latest updates and insights on Phibro Animal stock.
Phibro Animal Health Corporation (Nasdaq: PAHC) is a diversified global animal health and nutrition company with operations across Animal Health, Mineral Nutrition, and Performance Products. This news page aggregates company-issued updates and other coverage related to PAHC stock, helping readers follow developments that Phibro discloses through press releases and regulatory communications.
Phibro’s news flow frequently includes financial results and guidance, such as quarterly and full-year earnings releases and updates to financial outlook for future fiscal years. These announcements often detail net sales by segment, trends in medicated feed additives (MFAs), nutritional specialty products, vaccines, mineral nutrition products, and performance products, as well as commentary on factors like product demand, foreign currency impacts, and operating expenses.
Investors can also expect corporate and strategic announcements, including information about acquisitions or portfolio additions, such as the referenced MFA portfolio acquired from Zoetis, Inc., and enterprise programs like Phibro Forward, which the company describes as focused on efficiency, growth, and cultural engagement. Leadership and governance updates, including planned executive transitions and matters presented at the annual meeting of stockholders, are typically communicated through press releases and accompanying SEC filings.
Product and pipeline-related news is another key category. Phibro has highlighted developments in companion animal oral health, including the licensing agreement with Lighthouse Pharmaceuticals, Inc. for a proprietary compound for canine periodontal care and the national launch of Restoris piezoelectric dental gel for dogs with periodontal disease. Such releases describe product mechanisms, study results, and distribution plans.
In addition, Phibro issues dividend declarations, notices of participation in investor conferences, and details on upcoming webcasts and conference calls to discuss results. Readers interested in PAHC can use this page to monitor these recurring updates and review the company’s own descriptions of its performance, strategy, and product initiatives.
Phibro Animal Health Corporation (NASDAQ:PAHC) reported its Q1 2020 results with net sales of $195 million, a 3% increase year-over-year and net income rising to $12 million, up from $2.5 million. Diluted EPS reached $0.30, an increase of $0.24. The company noted strong performance in its core Animal Health segment, particularly in nutritional specialty products and vaccines, while Mineral Nutrition saw a decline. The outlook for Q2 forecasts net sales of about $205 million, reflecting ongoing recovery in the animal production industry.
Phibro Animal Health Corporation (NASDAQ:PAHC) will participate in the 29th Annual Credit Suisse Virtual Healthcare Conference on November 11, 2020, at 1:15 PM ET. Key executives, including Chairman and CEO Jack Bendheim, CFO Richard Johnson, and incoming CFO Damian Finio, will address financial analysts and investors. The presentation will be available live on the company’s Investor Relations Website, with a replay archived for later access. Phibro focuses on developing and supplying animal health and nutrition products to support healthy food production.
Phibro Animal Health Corporation (NASDAQ:PAHC) will release its first quarter financial results on November 4, 2020, after market close. A conference call and webcast are scheduled for November 5, 2020, at 9:00 AM ET.
Investors can participate in the call via phone or through a webcast available on the company's investor relations website. A replay will be accessible two hours after the live event. Phibro develops and supplies a wide range of animal health and nutrition products to support sustainable livestock production.